Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Catasys

Nasdaq:CATS
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CATS
Nasdaq
$269M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Catasys, Inc. provides big data predictive analytics, artificial intelligence and telehealth, and human intervention services to health plans and other third party payors. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Catasys has significant price volatility in the past 3 months.
CATS Share Price and Events
7 Day Returns
5.4%
NasdaqCM:CATS
1.9%
US Healthcare
-1.1%
US Market
1 Year Returns
21.5%
NasdaqCM:CATS
-1.7%
US Healthcare
-13.6%
US Market
CATS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Catasys (CATS) 5.4% 4.4% 2.7% 21.5% 46.4% 54%
US Healthcare 1.9% -10.3% -16.7% -1.7% 14.9% 15.7%
US Market -1.1% -17.8% -22.5% -13.6% 4.9% 16.3%
1 Year Return vs Industry and Market
  • CATS outperformed the Healthcare industry which returned -1.7% over the past year.
  • CATS outperformed the Market in United States of America which returned -13.6% over the past year.
Price Volatility
CATS
Industry
5yr Volatility vs Market

Value

 Is Catasys undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Catasys is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Catasys has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Catasys. This is due to cash flow or dividend data being unavailable. The share price is $16.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Catasys's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Catasys's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CATS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.56
NasdaqCM:CATS Share Price ** NasdaqCM (2020-04-02) in USD $16.08
United States of America Healthcare Industry PE Ratio Median Figure of 45 Publicly-Listed Healthcare Companies 20.62x
United States of America Market PE Ratio Median Figure of 2,943 Publicly-Listed Companies 12.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Catasys.

NasdaqCM:CATS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CATS Share Price ÷ EPS (both in USD)

= 16.08 ÷ -1.56

-10.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catasys is loss making, we can't compare its value to the US Healthcare industry average.
  • Catasys is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Catasys's expected growth come at a high price?
Raw Data
NasdaqCM:CATS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
29.8%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 1.59x
United States of America Market PEG Ratio Median Figure of 2,006 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Catasys, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Catasys's assets?
Raw Data
NasdaqCM:CATS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-1.44
NasdaqCM:CATS Share Price * NasdaqCM (2020-04-02) in USD $16.08
United States of America Healthcare Industry PB Ratio Median Figure of 95 Publicly-Listed Healthcare Companies 2.29x
United States of America Market PB Ratio Median Figure of 5,140 Publicly-Listed Companies 1.25x
NasdaqCM:CATS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CATS Share Price ÷ Book Value per Share (both in USD)

= 16.08 ÷ -1.44

-11.18x

* Primary Listing of Catasys.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catasys has negative assets, we can't compare the value of its assets to the US Healthcare industry average.

Next steps:

  1. Take a look at our analysis of CATS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Catasys's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Healthcare industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Catasys's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Catasys has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Catasys expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Catasys expected to grow at an attractive rate?
  • Unable to compare Catasys's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Catasys's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Catasys's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CATS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CATS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 29.8%
NasdaqCM:CATS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 60.8%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.6%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CATS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CATS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 145 -13 1
2020-12-31 87 -23 3
2020-04-02
NasdaqCM:CATS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 35 -17 -26
2019-09-30 29 -14 -18
2019-06-30 24 -11 -14
2019-03-31 20 -10 -13
2018-12-31 15 -9 -14
2018-09-30 13 -9 -15
2018-06-30 9 -8 -14
2018-03-31 8 -9 4
2017-12-31 8 -7 -14
2017-09-30 8 -7 -12
2017-06-30 9 -6 -17
2017-03-31 8 -6 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Catasys is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Catasys's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CATS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Catasys Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CATS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.22 -0.22 -0.22 1.00
2020-12-31 -1.04 -0.64 -1.43 2.00
2020-04-02
NasdaqCM:CATS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.56
2019-09-30 -1.13
2019-06-30 -0.88
2019-03-31 -0.81
2018-12-31 -0.89
2018-09-30 -0.97
2018-06-30 -0.89
2018-03-31 0.26
2017-12-31 -0.99
2017-09-30 -1.03
2017-06-30 -1.61
2017-03-31 -3.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Catasys will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Catasys's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Catasys has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Catasys performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Catasys's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Catasys does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Catasys's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Catasys's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Catasys's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Catasys Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CATS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 35.10 -25.66 33.20
2019-09-30 28.96 -18.42 26.71
2019-06-30 24.49 -14.21 23.57
2019-03-31 20.08 -12.92 19.82
2018-12-31 15.18 -14.21 17.68
2018-09-30 12.59 -15.45 17.19
2018-06-30 9.41 -14.18 14.59
2018-03-31 7.81 3.95 13.05
2017-12-31 7.72 -13.61 11.81
2017-09-30 8.47 -12.44 10.46
2017-06-30 8.61 -16.77 10.08
2017-03-31 8.17 -35.41 9.28
2016-12-31 7.08 -17.94 8.84
2016-09-30 4.55 -15.32 8.44
2016-06-30 3.75 -15.39 8.22
2016-03-31 3.00 -11.26 8.50
2015-12-31 2.71 -7.22 9.05
2015-09-30 2.59 -10.16 8.78
2015-06-30 2.42 -2.89 8.41
2015-03-31 2.26 -29.75 7.70
2014-12-31 2.03 -27.13 6.30
2014-09-30 1.32 -25.78 5.95
2014-06-30 1.06 -24.65 5.60
2014-03-31 0.82 -3.18 5.13
2013-12-31 0.75 -2.92 5.43
2013-09-30 0.49 -8.20 5.83
2013-06-30 0.53 -9.38 6.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Catasys has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Catasys has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Catasys improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Catasys's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Catasys has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Catasys's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Catasys's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Catasys is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Catasys's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Catasys's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Catasys has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Catasys Company Filings, last reported 3 months ago.

NasdaqCM:CATS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -23.91 31.60 13.61
2019-09-30 -17.72 29.87 15.90
2019-06-30 -12.16 15.54 7.06
2019-03-31 -10.68 10.03 1.30
2018-12-31 -8.97 7.47 3.16
2018-09-30 -7.71 7.42 4.86
2018-06-30 -4.63 4.87 5.60
2018-03-31 -0.92 0.00 1.35
2017-12-31 0.90 0.00 4.78
2017-09-30 3.30 0.00 6.93
2017-06-30 6.35 0.00 9.22
2017-03-31 -44.60 10.05 0.29
2016-12-31 -25.33 9.80 0.85
2016-09-30 -24.58 8.65 1.84
2016-06-30 -17.39 6.11 0.05
2016-03-31 -12.84 4.68 0.26
2015-12-31 -8.72 3.66 0.92
2015-09-30 -12.10 2.01 0.23
2015-06-30 -5.26 2.34 0.15
2015-03-31 -40.42 0.20 0.08
2014-12-31 -41.22 0.00 0.71
2014-09-30 -41.18 0.00 1.53
2014-06-30 -42.92 0.00 1.14
2014-03-31 -15.89 0.00 0.72
2013-12-31 -18.04 0.00 1.14
2013-09-30 -16.59 0.00 0.42
2013-06-30 -17.32 0.00 1.62
  • Catasys has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Catasys's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Catasys has less than a year of cash runway based on current free cash flow.
  • Catasys has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.5% each year.
X
Financial health checks
We assess Catasys's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Catasys has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Catasys's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Catasys dividends.
If you bought $2,000 of Catasys shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Catasys's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Catasys's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CATS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1943 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CATS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-02

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Catasys has not reported any payouts.
  • Unable to verify if Catasys's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Catasys's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Catasys has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Catasys's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Catasys afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Catasys has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Catasys's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Terren Peizer
COMPENSATION $2,411,806
AGE 59
TENURE AS CEO 17.2 years
CEO Bio

Mr. Terren S. Peizer has been Chairman and Chief Executive Officer of BioVie Inc since July 3, 2018. He is Founder of Neurmedix, Inc. and serves as its Chairman and Chief Executive Officer. Mr. Peizer serves as Chairman and Managing Director at Crede CG II, Ltd. Mr. Peizer founded Catasys, Inc. (also known as Hythiam Inc.) in February 2003 and has been its Chairman and Chief Executive Officer since February 2003. He served as President of Catasys, Inc. He is Founder of Crede Capital Group and serves as its Chairman and Chief Executive Officer. He is Founder of Acuitas Group Holdings, LLC and serves as its Chairman and Chief Executive Officer. Mr. Peizer serves as Chairman and Chief Executive Officer of Intellect Capital Group LLC. He is the Chairman and Managing Director at Socius Capital Group, LLC. Mr. Peizer served as President of Hythiam. He served as the Chief Executive Officer at Clearant, Inc., from April 1999 to October 2003. He Founded Clearant, Inc. in April 1999. Mr. Peizer served as the Chairman and Chief Executive Officer at Beachwood Financial Company Inc. from 1993 to 1997. He served as Chairman and Chief Executive Officer at Financial Group Holdings Inc. from 1990 to 1993. He served as the President and Vice Chairman at Hollis-Eden Pharmaceuticals, Inc. from February 1997 to February 1999. He has a background in venture capital, investing, mergers and acquisitions, corporate finance. Mr. Peizer served senior executive positions with the investment banking firms Goldman Sachs and First Bostonand. He served as senior member of the investment banking firm of Drexel Burnham Lambert Inc. from 1985 to 1990. Mr. Peizer served various senior executive positions with several technology and biotech companies, where he assisted the companies with assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, investor and public relations and capital formation. He serves as the Chairman of Pacific Spirit Inc. He served as Chairman of Brightcube, Inc., from June 2000 to October 1, 2002 and Cray Inc., from June 1999 to December 2000. Mr. Peizer served as the Chairman of Clearant, Inc., from April 1999 to October 2004. He has been a Director of Hythiam Inc. since 2003. Mr. Peizer served as Executive Chairman of Xcorporeal, Inc. since August 2007 until October 2008. He has been Executive Director of Xcorporeal, Inc. since August 2006 and Catasys, Inc. since February 2003. He served as a Director of Clearant, Inc. until February 2005. He served as a Director of Brightcube Inc. since June 2000. He served as Director of Cray Inc., from June 1999 to May 2003. He holds B.S.E. degree in Finance from The Wharton School of Finance and Commerce.

CEO Compensation
  • Terren's compensation has increased whilst company is loss making.
  • Terren's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Catasys management team in years:

1.1
Average Tenure
47
Average Age
  • The average tenure for the Catasys management team is less than 2 years, this suggests a new team.
Management Team

Terren Peizer

TITLE
Founder
COMPENSATION
$2M
AGE
59
TENURE
17.2 yrs

Curt Medeiros

TITLE
President & COO
TENURE
0.3 yrs

Brandon LaVerne

TITLE
Chief Financial Officer
AGE
47
TENURE
0.1 yrs

Jeremiah Stone

TITLE
Chief Technology Officer
TENURE
1.8 yrs

Greg McLane

TITLE
Chief Marketing & Strategy Officer
TENURE
4.6 yrs

Sandy Gyenes

TITLE
Vice President of Human Resources
TENURE
0.4 yrs

Susan Etzel

TITLE
Senior Vice President of Finance
COMPENSATION
$170K
AGE
45
TENURE
2.9 yrs

Patrick Traynor

TITLE
Senior Vice President of Engineering & Operations
TENURE
1.1 yrs

Peter Bearse

TITLE
Chief Data Scientist & Senior VP

Michael Wain

TITLE
Senior Vice President of Member Engagement
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Catasys board of directors in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Catasys board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard Berman

TITLE
Independent Director
COMPENSATION
$132K
AGE
73
TENURE
6.2 yrs

Terren Peizer

TITLE
Founder
COMPENSATION
$2M
AGE
59
TENURE
17.2 yrs

Michael Sherman

TITLE
Independent Director
COMPENSATION
$124K
AGE
60
TENURE
2.8 yrs

Ed Zecchini

TITLE
Independent Director
COMPENSATION
$44K
AGE
58
TENURE
1.4 yrs

Diane Seloff

TITLE
Independent Director
COMPENSATION
$39K
AGE
55
TENURE
1.5 yrs

Rob Rebak

TITLE
Director
TENURE
0.8 yrs

Gus Giraldo

TITLE
Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Catasys individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
30. Mar 20 Buy Robert Rebak Individual 24. Mar 20 24. Mar 20 3,200 $10.33 $33,056
24. Mar 20 Buy Curt Medeiros Individual 23. Mar 20 23. Mar 20 21,835 $9.64 $200,040
24. Mar 20 Buy Curt Medeiros Individual 16. Mar 20 16. Mar 20 18,262 $11.50 $199,987
27. Feb 20 Sell Coast Asset Management, LLC Company 20. Feb 20 20. Feb 20 -6,922 $18.77 $-129,911
21. Feb 20 Sell Coast Asset Management, LLC Company 19. Feb 20 19. Feb 20 -71,852 $18.80 $-1,350,983
10. Feb 20 Sell Coast Asset Management, LLC Company 06. Feb 20 06. Feb 20 -796 $18.84 $-15,000
07. Feb 20 Sell Coast Asset Management, LLC Company 05. Feb 20 05. Feb 20 -25,256 $18.80 $-474,793
16. Jul 19 Sell Coast Asset Management, LLC Company 01. Jul 19 15. Jul 19 -195,197 $19.86 $-3,829,453
02. Jul 19 Sell Coast Asset Management, LLC Company 24. May 19 28. Jun 19 -224,286 $19.95 $-4,183,150
16. May 19 Sell Coast Asset Management, LLC Company 15. May 19 15. May 19 -42,229 $18.45 $-778,914
10. May 19 Sell Coast Asset Management, LLC Company 09. May 19 10. May 19 -16,692 $18.24 $-288,594
22. May 19 Sell Coast Asset Management, LLC Company 16. May 19 20. May 19 -115,000 $19.91 $-2,231,094
15. May 19 Sell Coast Asset Management, LLC Company 13. May 19 14. May 19 -34,500 $18.27 $-627,230
08. May 19 Sell Coast Asset Management, LLC Company 07. May 19 08. May 19 -164,031 $17.16 $-2,713,807
25. Apr 19 Sell Coast Asset Management, LLC Company 24. Apr 19 25. Apr 19 -135,773 $15.28 $-2,034,694
11. Apr 19 Sell Coast Asset Management, LLC Company 11. Apr 19 11. Apr 19 -99 $13.88 $-1,374
29. Apr 19 Sell Coast Asset Management, LLC Company 26. Apr 19 29. Apr 19 -50,815 $15.98 $-801,895
X
Management checks
We assess Catasys's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Catasys has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Catasys, Inc.'s (NASDAQ:CATS) CEO Pay Compare Well With Peers?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … See our latest analysis for Catasys How Does Terren Peizer's Compensation Compare With Similar Sized Companies? … pays its CEO, and compared it to the amount paid by similar sized companies.

Simply Wall St -

Catasys (NASDAQ:CATS) Has Us Worried With Its Last Reported Debt Levels

NasdaqCM:CATS Historical Debt, July 3rd 2019 A Look At Catasys's Liabilities We can see from the most recent balance sheet that Catasys had liabilities of US$8.48m falling due within a year, and liabilities of US$9.41m due beyond that. … Either way, since Catasys does have more debt than cash, it's worth keeping an eye on its balance sheet. … When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt.

Simply Wall St -

If You Had Bought Catasys (NASDAQ:CATS) Shares Three Years Ago You'd Have Made 313%

View our latest analysis for Catasys Because Catasys is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last 3 years Catasys saw its revenue grow at 48% per year.

Simply Wall St -

What Kind Of Shareholder Owns Most Catasys, Inc. (NASDAQ:CATS) Stock?

Insider Ownership Of Catasys The definition of company insiders can be subjective, and does vary between jurisdictions. … Insider ownership is positive when it signals leadership are thinking like the true owners of the company. … However, high insider ownership can also give immense power to a small group within the company.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Catasys, Inc. (NASDAQ:CATS)?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … (NASDAQ:CATS), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Does Catasys, Inc. (NASDAQ:CATS) Have A Particularly Volatile Share Price?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Why Catasys, Inc.'s (NASDAQ:CATS) CEO Pay Matters To You

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … Then we'll look at a snap shot of the business growth. … How Does Terren Peizer's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Do Directors Own Catasys, Inc. (NASDAQ:CATS) Shares?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at the our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about CATS

Simply Wall St -

Are Insiders Buying Catasys, Inc. (NASDAQ:CATS) Stock?

So we'll take a look at whether insiders have been buying or selling shares in Catasys, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … In the last twelve months there was more buying than selling by Catasys insiders

Simply Wall St -

Does Market Volatility Impact Catasys Inc's (NASDAQ:CATS) Share Price?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Company Info

Description

Catasys, Inc. provides big data predictive analytics, artificial intelligence and telehealth, and human intervention services to health plans and other third party payors. The company offers OnTrak solution, which is an integrated suite of services that includes evidence-based psychosocial and medical interventions delivered either in-person or through telehealth, nurse-led care coaching, and local community support. Its OnTrak solution treats members with behavioral conditions that cause or exacerbate co-existing medical conditions, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The company was formerly known as Hythiam, Inc. and changed its name to Catasys, Inc. in March 2011. Catasys, Inc. was incorporated in 2003 and is based in Santa Monica, California.

Details
Name: Catasys, Inc.
CATS
Exchange: NasdaqCM
Founded: 2003
$268,969,581
16,726,964
Website: http://catasys.com
Address: Catasys, Inc.
2120 Colorado Boulevard,
Suite 230,
Santa Monica,
California, 90404,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CATS Common Stock Nasdaq Capital Market US USD 30. Sep 2003
DB HY1N Common Stock Deutsche Boerse AG DE EUR 30. Sep 2003
Number of employees
Current staff
Staff numbers
395
Catasys employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/02 23:51
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.